{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:20:31Z","timestamp":1780626031295,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejpn.2021.01.005","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T11:19:57Z","timestamp":1611314397000},"page":"10-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practice"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2081-8988","authenticated-orcid":false,"given":"Joseph","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Scott","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Wheless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Galer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-2862","authenticated-orcid":false,"given":"Arnold","family":"Gammaitoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"s2","key":"10.1016\/j.ejpn.2021.01.005_bib1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/epi4.12239","article-title":"From clinical trials of antiepileptic drugs to treatment","volume":"3","author":"Perucca","year":"2018","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ejpn.2021.01.005_bib2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.2009.107805","article-title":"Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice","volume":"69","author":"Moore","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejpn.2021.01.005_bib3","series-title":"What Is an NNT?","author":"Moore","year":"2009"},{"key":"10.1016\/j.ejpn.2021.01.005_bib4","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO Study Group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejpn.2021.01.005_bib5","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2021.01.005_bib6","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.ejpn.2021.01.005_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2021.01.005_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol."},{"issue":"15 suppl","key":"10.1016\/j.ejpn.2021.01.005_bib9","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1212\/WNL.94.15_supplement.1985","article-title":"Real-world experience with ZX008 (fenfluramine HCl) for the treatment of seizures in Dravet syndrome: initial report from United States expanded access program","volume":"94","author":"Perry","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2021.01.005_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2474-12-165","article-title":"Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis","volume":"12","author":"Peloso","year":"2011","journal-title":"BMC Muscoskel. Disord."},{"key":"10.1016\/j.ejpn.2021.01.005_bib11","first-page":"26","article-title":"Quantifying clinical relevance","volume":"11","author":"Citrome","year":"2014","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.ejpn.2021.01.005_bib12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1528-1157.2000.tb00186.x","article-title":"The value of the number-needed-to-treat method in antiepileptic drug trials","volume":"41","author":"Lesaffre","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2021.01.005_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/seiz.2001.0497","article-title":"The \u2019number needed to treat\u2019 with Levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs)","volume":"10","author":"van Rijckevorsel","year":"2001","journal-title":"Seizure"},{"key":"10.1016\/j.ejpn.2021.01.005_bib14","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1528-1167.2011.03047.x","article-title":"Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis","volume":"52","author":"Costa","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2021.01.005_bib15","series-title":"Drug Class Update with New Drug Evaluations: Antiepileptics. Salem","author":"Moretz","year":"2019"},{"issue":"11","key":"10.1016\/j.ejpn.2021.01.005_bib16","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/epi.16722","article-title":"Fenfluramine HCl (Fintepla\u00ae) provides long-term clinically meaningful reduction in seizure frequency: analysis of an ongoing open-label extension study","volume":"61","author":"Sullivan","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2021.01.005_bib17","series-title":"Profound reduction in seizure frequency (\u226575%) leads to improved everyday executive function: analysis from a phase 3 study of ZX008 (fenfluramine HCL) in children\/young adults with Dravet syndrome [abstract]","author":"Bishop","year":"2019"},{"key":"10.1016\/j.ejpn.2021.01.005_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.yebeh.2017.06.012","article-title":"Life impact of caregiving for severe childhood epilepsy: results of expert panels and caregiver focus groups","volume":"74","author":"Jensen","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ejpn.2021.01.005_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pediatrneurol.2020.01.005","article-title":"Dravet syndrome: a review of current management","volume":"107","author":"Wheless","year":"2020","journal-title":"Pediatr. Neurol."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379821000052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379821000052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:37:10Z","timestamp":1761071830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379821000052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":19,"alternative-id":["S1090379821000052"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2021.01.005","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2021.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}